2-Hydroxy-5,6-dihydro-3H-pyrrolo<1.2.3-de>-chinoxalin-3-on | 2759-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-Hydroxy-5,6-dihydro-3H-pyrrolo<1.2.3-de>-chinoxalin-3-on
• 英文别名: 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-dione；1,9-Diazatricyclo[6.3.1.0^{4,12}]dodeca-4,6,8(12)-triene-10,11-dione；1,9-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-triene-10,11-dione
• CAS: 2759-27-5
• 化学式: C₁₀H₈N₂O₂
• 分子量: 188.186
• InChiKey: CQMYAIJFGMSTHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。
• Dendrimers as Molecular Translocators
  申请人：Goodman Murray

  公开号：US20080221020A1

  公开（公告）日：2008-09-11

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  运输分子包括一个树状分子和一个生物活性分子。这种运输分子的树状分子包括至少一个鸟氨酸基团，至少一个质子化的鸟氨酸基团，至少一个保护的鸟氨酸基团，至少一个酰胺基团，至少一个质子化的酰胺基团，至少一个保护的酰胺基团，至少一个尿素基团，至少一个质子化的尿素基团，至少一个保护的尿素基团，至少一个硫脲基团，至少一个质子化的硫脲基团，或者至少一个保护的硫脲基团。生物活性分子与树状分子结合。一种增加药物生物利用度的方法包括将药物与本发明的树状分子结合。
• Tricyclic quinoxalinedione derivatives
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0627434A1

  公开（公告）日：1994-12-07

  A tricyclic quinoxalinedione derivative represented by the formula 1:    wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro;    R¹ represents hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl;    G represents -CONR²- or -NR²CO-, wherein R² represents hydrogen or alkyl;    J represents an acidic group or a group which is convertible thereto in vivo;    E represents an basic group or a group which is convertible thereto in vivo;    Y represents a single bond, alkylene, alkenylene, substituted alkylene, or Y¹-Q-Y², wherein Y¹ represents a single bond or alkylene, Y² represents alkylene, and Q represents a heteroatom selected from oxygen or sulfur;    Z represents alkylene.    or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.

  由式 1 表示的三环喹喔啉二酮衍生物： 其中 X 代表氢、烷基、卤素、氰基、三氟甲基或硝基； R¹ 代表氢、烷基、环烷基或环烷基烷基； G 代表-CONR²-或-NR²CO-，其中 R² 代表氢或烷基； J 代表酸性基团或在体内可转化为酸性基团的基团； E 代表碱性基团或体内可转化为碱性基团的基团； Y 代表单键、亚烷基、烯基、取代亚烷基或 Y¹-Q-Y²，其中 Y¹ 代表单键或亚烷基，Y² 代表亚烷基，Q 代表选自氧或硫的杂原子； Z 代表亚烷基。 或其药学上可接受的盐，这些化合物是 NMDA 受体甘氨酸结合位点的选择性拮抗剂。
• Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
  申请人：Medinox, Inc.

  公开号：US20030087840A1

  公开（公告）日：2003-05-08

  In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or “DC”) and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

  根据本发明，提供了一氧化氮清除剂（如二硫代氨基甲酸盐或 "DC"）和药理活性剂（如非甾体抗炎药）的共轭物。本发明共轭物提供了一类新的药理活性制剂（如消炎药），由于本文所述对药理活性制剂的改性所带来的保护作用，其副作用发生率大大降低。此外，本发明共轭物比未经改性的药理活性剂更有效，因为当本发明共轭物被裂解时，除了游离的药理活性剂外，一氧化氮清除剂（如二硫代氨基甲酸盐）也会同时产生，从而保护与药理活性剂接触的细胞和组织免受一氧化氮过量产生的潜在破坏作用。
• COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS
  申请人：Medinox, Inc.

  公开号：EP0866695A1

  公开（公告）日：1998-09-30